EFFICACY AND SAFETY OF USTEKINUMAB FOR CROHN'S DISEASE: RESULTS FROM IM-UNITI LONG-TERM EXTENSION THROUGH 3 YEARS

(1) University of California San Diego,La Jolla,United States

(2) University Hospital Gasthuisberg,Leuven,Belgium

(3) Janssen Research & Development, LLC,Spring House,United States

(4) Janssen Scientific Affairs, LLC,Horsham,United States

(5) Icahn School of Medicine at Mount Sinai,New York,United States

(6) Northwestern University Feinberg School of Medicine,Chicago,United States

(7) Cedars-Sinai Medical Center,Los Angeles,United States

(8) University of Birmingham, Institute of Immunology and Immunotherapy,Birmingham,United Kingdom

(9) University of Stellenbosch,Stellenbosch,South Africa

(10) Robarts Research Institute,London,Canada



This item was part of UEG Week 2018

This item can be cited as: United European Gastroenterology Journal 2018; 6 (Supplement 1)